紫杉醇脂质体与紫杉醇联合卡培他滨一线治疗晚期胃癌疗效比较

Comparison of Efficacy of Paclitaxel Liposome or Paclitaxel plus Capecitabine in the First-line Treatment of Advanced Gastric Cancer

目的比较紫杉醇脂质体与紫杉醇联合卡培他滨一线治疗晚期胃癌的疗效和安全性。方法 49例晚期胃癌患者分为2组,分别接受紫杉醇脂质体联合卡培他滨和紫杉醇联合卡培他滨治疗。结果紫杉醇脂质体联合卡培他滨组与紫杉醇联合卡培他滨组的有效率分别为46.2%和43.5%(P>0.05),疾病控制率分别为73.1%和69.6%(P>0.05),中位疾病进展时间分别为5.7个月和5.4个月(P>0.05),中位生存时间分别为10.3个月和9.2个月(P>0.05)。紫杉醇脂质体联合卡培他滨组毒副反应中关节肌肉酸痛及恶心呕吐发生率要低于紫杉醇联合卡培他滨组(P<0.05)。结论紫杉醇脂质体与紫杉醇联合卡培他滨一线治疗晚期胃癌疗效相当,毒副反应更轻。

Objective To compare the efficacy and toxicities of paclitaxel liposome or paelitaxel plus capecitabine in the first-line treatment of patients with advanced gastric cancer. Methods Forty-nine patients with advanced gastric cancer were divided into two groups, and were respectively treated with paclitaxel liposome or paclita- xel plus capecitabine. Results In the paclitaxel liposome plus capecitabine group and the paclitaxel plus capecit- abine group, the response rate was 46.2% and 43.5% （P 〉 0.05 ） , the disease control rate was 73. I% and 69.6% （ P 〉 0.05 ）, the median time to progress was 5.7 months and 5.4 months （ P 〉 0.05 ） and the median over- all survival time was 10.3 months and 9.2 months （ P 〉 0.05 ） respectively. Compared with the paclitaxel plus capecitabine group, there were less toxicities such as muscle and joint pain, nausea and vomiting in the paclitaxel liposome plus capecitabine group （ P 〈 0.05 ）. Conclusion Paclitaxel liposome or paclitaxel plus capecitabine are effective in the first-line treatment of patients with advanced gastric cancer, but paclitaxel liposome plus capecitabine has less toxicities than paclitaxel plus capecitabine.